Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation

Journal of Clinical Investigation

Volumn 118, Issue 12, 2008, Pages 3943-3953

  Hui, Lijian ^a   Zatloukal, Kurt ^b   Scheuch, Harald ^a   Stepniak, Ewa ^a,d   Wagner, Erwin F ^c  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

P21 ACTIVATED KINASE; STRESS ACTIVATED PROTEIN KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER REGENERATION; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; P21 GENE; PRIORITY JOURNAL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; LIVER REGENERATION; MALE; MICE; MICE, KNOCKOUT; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 8; NEOPLASMS, EXPERIMENTAL;

EID: 57449109370     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37156     Document Type: Article

References (49)

1. Farazi, P.A., and DePinho, R.A. 2006. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer. 6:674-687.
2. Eferl, R., et al. 2003. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell. 112:181-192.
3. Hui, L., et al. 2007. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat. Genet. 39:741-749.
4. Maeda, S., Kamata, H., Luo, J.L., Leffert, H., and Karin, M. 2005. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 121:977-990.
5. Sakurai, T., Maeda, S., Chang, L., and Karin, M. 2006. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. U. S. A. 103:10544-10551.
6. Sakurai, T., et al. 2008. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell. 14:156-165.
7. Weston, C.R., and Davis, R.J. 2007. The JNK signal transduction pathway. Curr. Opin. Cell Biol. 19:142-149.
8. Hochedlinger, K., Wagner, E.F., and Sabapathy, K. 2002. Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis. Oncogene. 21:2441-2445.
9. Wada, T., et al. 2008. Antagonistic control of cell fates by JNK and p38-MAPK signaling. Cell Death Differ. 15:89-93.
10. Sabapathy, K., et al. 2004. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol. Cell. 15:713-725.
11. Jaeschke, A., et al. 2006. JNK2 is a positive regulator of the cJun transcription factor. Mol. Cell. 23:899-911.
12. Papa, S., et al. 2008. Gadd45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling. J. Clin. Invest. 118:1911-1923.
13. Schwabe, R.F., et al. 2003. c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology. 37:824-832.
14. Bain, J., McLauchlan, H., Elliott, M., and Cohen, P. 2003. The specificities of protein kinase inhibitors: an update. Biochem. J. 371:199-204.
15. She, Q.B., Chen, N., Bode, A.M., Flavell, R.A., and Dong, Z. 2002. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 62:1343-1348.
16. Tong, C., et al. 2007. c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am. J. Pathol. 171:297-303.
17. Hasselblatt, P., Gresh, L., Kudo, H., Guinea-Viniegra, J., and Wagner, E.F. 2008. The role of the transcription factor AP-1 in colitis-associated and beta-catenin-dependent intestinal tumorigenesis in mice. Oncogene. 27:6102-6109. doi:10.1038/onc.2008.211.
18. Shibata, W., et al. 2008. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res. 68:5031-5039.
19. Chen, N., et al. 2001. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res. 61:3908-3912.
20. Fausto, N., Campbell, J.S., and Riehle, K.J. 2006. Liver regeneration. Hepatology. 43:S45-53.
21. Lin, W.W., and Karin, M. 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117:1175- 1183.
22. Lopez-Bergami, P., et al. 2007. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell. 11:447-460.
23. Vivanco, I., et al. 2007. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell. 11:555-569.
24. Behrens, A., et al. 2002. Impaired postnatal hepa tocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J. 21:1782-1790.
25. Matsuzaki, K., et al. 2007. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology. 46:48-57.
26. Wu, H., et al. 1996. Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. Genes Dev. 10:245-260.
27. Stepniak, E., et al. 2006. c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. Genes Dev. 20:2306-2314.
28. el-Deiry, W.S., et al. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817-825.
29. Herold, S., et al. 2002. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol. Cell. 10:509-521.
30. Seoane, J., Le, H.V., and Massague, J. 2002. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 419:729-734.
31. Oskarsson, T., et al. 2006. Skin epidermis lacking the c-Myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene. Genes Dev. 20:2024-2029.
32. Sabapathy, K., and Wagner, E.F. 2004. JNK2: a negative regulator of cellular proliferation. Cell Cycle. 3:1520-1523.
33. Sanna, M.G., Duckett, C.S., Richter, B.W., Thompson, C.B., and Ulevitch, R.J. 1998. Selective activation of JNK1 is necessary for the anti-apoptotic activity of hILP. Proc. Natl. Acad. Sci. U. S. A. 95:6015-6020.
34. David, J.P., Sabapathy, K., Hoffmann, O., Idarraga, M.H., and Wagner, E.F. 2002. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J. Cell. Sci. 115:4317-4325.
35. Mizukami, J., et al. 2002. Receptor activator of NFkappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol. Cell. Biol. 22:992-1000.
36. Hasselblatt, P., Rath, M., Komnenovic, V., Zatloukal, K., and Wagner, E.F. 2007. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 104:17105-17110.
37. Kuntzen, C., et al. 2005. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res. 65:6780-6788.
38. Fan, Y., et al. 2007. c-Jun NH2-terminal kinase decreases ubiquitination and promotes stabilization of p21(WAF1/CIP1) in K562 cell. Biochem. Biophys. Res. Commun. 355:263-268.
39. Kim, G.Y., et al. 2002. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J. Biol. Chem. 277:29792-29802.
40. Noguchi, K., Kokubu, A., Kitanaka, C., Ichijo, H., and Kuchino, Y. 2001. ASK1-signaling promotes c-Myc protein stability during apoptosis. Biochem. Biophys. Res. Commun. 281:1313-1320.
41. Bowman, T., et al. 2001. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. U. S. A. 98:7319-7324.
42. Buchholz, M., et al. 2006. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J. 25:3714-3724.
43. Kallunki, T., et al. 1994. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev. 8:2996-3007.
44. Cui, J., et al. 2005. Identification of a specific domain responsible for JNK2alpha2 autophosphorylation. J. Biol. Chem. 280:9913-9920.
45. Engelman, J.A., et al. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039-1043.
46. Stommel, J.M., et al. 2007. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 318:287-290.
47. Abou-Alfa, G.K., et al. 2006. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24:4293-4300.
48. Llovet, J.M., et al. 2008. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359:378-390.
49. Borsello, T., et al. 2003. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 9:1180-1186.